Citigroup
CRXT

Citigroup’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

Citigroup’s Portfolio CRXT Stock Details CRXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-18,000
Closed -$7K – 6646
2022
Q2 		$7K Buy
18,000
+10,600
+143% +$7.42K ﹤0.01% 5529
2022
Q1 		$11K Buy
+7,400
New +$9.4K ﹤0.01% 5506

Other funds holding CRXT

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Citigroup's CRXT Position: Q3 2022 in Review

Citigroup sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q3 2022, closing a stake of 18,000 shares — an estimated $7K sold.

Citigroup first reported a position in CRXT in Q1 2022 and held it in 2 quarters. The position peaked at $11K in Q1 2022. 2 funds tracked by Wall St. Rank hold CRXT as of Q3 2022.

  • Citigroup reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Citigroup sold 18,000 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q3 2022, an estimated $7K.
  • Citigroup first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • Citigroup's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $11K in Q1 2022.
  • 2 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q3 2022.

Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.